Biotechnology Trademark Law In Russia.

1. Introduction

Biotechnology Trademark Law in Russia concerns the legal protection, registration, ownership, licensing, commercial use and enforcement of trademarks associated with biotechnology products, pharmaceutical preparations, genetic engineering, vaccines, biological research, laboratory technologies, diagnostic products, medical devices and other life-science innovations.

Russia does not have a separate trademark statute exclusively governing biotechnology. Instead, biotechnology trademarks are regulated primarily under Part IV of the Civil Code of the Russian Federation, together with pharmaceutical, medical-product, advertising, competition and consumer-protection legislation.

The central purpose of trademark protection is to distinguish the commercial origin of biotechnology products and prevent consumers, patients, healthcare institutions and research organisations from confusing one manufacturer's products with those of another.

For example:

A biotechnology company may register a distinctive name for a genetically engineered medicine.

A vaccine manufacturer may protect its vaccine brand.

A genetic-testing company may register a distinctive diagnostic-service mark.

A biotechnology laboratory may protect its commercial name and logo.

A manufacturer of cell-based therapies may protect the brand under which its products are marketed.

Trademark protection is particularly important in biotechnology because confusion between product identities can have consequences beyond ordinary commercial competition, including patient safety, treatment selection, product traceability and public confidence.

Russia's official intellectual-property framework recognises trademarks as protected means of individualisation under Part IV of the Civil Code.

rospatent.gov.ru+1

 

2. Legal Framework Governing Biotechnology Trademarks

The principal legislation and regulatory instruments include:

Legal instrumentRelevance to biotechnology trademarks
Russian Civil Code, Part IVMain legislation governing trademark rights
Article 1225Recognition of trademarks as intellectual property
Article 1229General rules on exclusive intellectual-property rights
Article 1477Definition and legal nature of trademarks
Article 1479Territorial scope of trademark protection
Article 1480State registration of trademarks
Article 1482Types of registrable trademarks
Article 1483Grounds for refusing trademark registration
Article 1484Exclusive rights of trademark owners
Article 1486Termination of trademark rights for non-use
Article 1487Exhaustion of trademark rights
Article 1488Assignment of exclusive trademark rights
Article 1490Form and registration of trademark agreements
Article 1491Duration of trademark rights
Article 1515Liability for unlawful trademark use

Other relevant legislation includes:

Federal Law No. 61-FZ of 12 April 2010, On Circulation of Medicines.

Federal Law No. 323-FZ of 21 November 2011, On the Fundamentals of Health Protection of Citizens in the Russian Federation.

Federal Law No. 38-FZ of 13 March 2006, On Advertising.

Federal Law No. 135-FZ of 26 July 2006, On Protection of Competition.

Federal Law No. 184-FZ of 27 December 2002, On Technical Regulation.

These laws operate alongside the Civil Code. Pharmaceutical product approval and trademark registration are separate legal procedures: registration of a brand does not itself authorise the manufacture or sale of a medicinal product.

3. Meaning and Scope of Biotechnology Trademarks

Under Article 1477 of the Russian Civil Code, a trademark is a designation serving to individualise goods, while service marks individualise services.

Article 1482 recognises different types of trademarks, including:

Word marks.

Figurative marks.

Three-dimensional marks.

Combined marks.

Other legally registrable designations.

In biotechnology, these categories can cover several commercial activities.

A. Pharmaceutical biotechnology

Examples include distinctive names for:

Recombinant proteins.

Monoclonal antibodies.

Gene-therapy products.

Cell therapies.

Biological medicines.

Therapeutic vaccines.

B. Agricultural biotechnology

Examples include brands for:

Genetically modified agricultural products.

Biological pesticides.

Microbial fertilisers.

Agricultural diagnostic products.

Biotechnology-based seeds.

C. Medical biotechnology

Examples include:

Molecular diagnostic kits.

Genetic testing services.

Laboratory-developed products.

Biotechnology-based medical devices.

Regenerative medicine products.

D. Research and laboratory biotechnology

Examples include:

Commercial laboratory services.

DNA sequencing services.

Biobanking services.

Contract research services.

Biotechnology research platforms.

The trademark must distinguish commercial origin. It cannot simply monopolise scientific terminology or the name of a biological substance.

4. Trademark Registration and Biotechnology Products

The principal registration authority is the Federal Service for Intellectual Property, commonly known as Rospatent.

A. Application procedure

A biotechnology business seeking trademark protection generally follows these steps:

Selection of a trademark: Choose a distinctive brand name, logo or other registrable designation.

Trademark search: Examine existing Russian registrations and pending applications.

Classification: Identify the relevant goods and services under the Nice Classification.

Application: Submit the designation, applicant information and specification of goods or services.

Formal examination: Rospatent examines the application documents.

Substantive examination: The authority evaluates distinctiveness, earlier rights and statutory restrictions.

Registration: Following acceptance and payment of the prescribed fees, the mark is entered into the State Register.

Renewal: The trademark owner must renew the registration when required.

B. Relevant Nice Classification classes

ClassBiotechnology-related products or services
Class 1Biological preparations for industrial and scientific purposes
Class 5Pharmaceutical and medical preparations, vaccines and certain diagnostic reagents
Class 9Scientific and laboratory instruments and certain diagnostic apparatus
Class 10Medical and surgical apparatus
Class 35Business and commercial services
Class 40Treatment and processing of materials
Class 42Scientific research, biotechnology research and laboratory services
Class 44Medical, healthcare and certain diagnostic services

The precise classification depends on the actual nature and intended function of the product or service. A biotechnology company may require protection in several classes.

Rospatent's guidance recognises word, figurative, three-dimensional and combined marks, with applications assessed against the Civil Code's registration requirements.

brics.rospatent.gov.ru+1

 

5. Distinctiveness and Scientific Terminology

Article 1483 is especially important for biotechnology businesses.

It prohibits registration of designations that lack distinctive character or consist exclusively of generic, customary or descriptive elements.

This creates several important legal issues.

A. Generic biological terminology

A company cannot ordinarily obtain exclusive trademark ownership over generic scientific names such as:

DNA.

RNA.

Protein.

Genome.

Insulin.

Vaccine.

Stem cells.

These expressions may be used by different businesses to describe scientific substances, products or technologies.

B. Descriptive biotechnology terminology

Names that merely describe the characteristics or intended purposes of products may also face refusal.

For example, a proposed mark consisting solely of the words "GENE TESTING" for genetic testing services may lack the required distinctiveness.

C. Acquired distinctiveness

Article 1483(1.1) recognises that a designation may qualify for registration if it has acquired distinctive character through use.

A biotechnology company may therefore submit evidence such as:

Duration of commercial use.

Sales and distribution records.

Advertising expenditure.

Market recognition.

Consumer surveys.

Commercial documents.

Evidence of recognition among relevant professional customers.

D. Misleading trademarks

A designation must not mislead consumers regarding the product's characteristics, origin or manufacturer.

For example, a company should not market an ordinary laboratory reagent under a designation that falsely suggests it is an officially certified therapeutic vaccine.

The registration restrictions and acquired-distinctiveness exception are set out in Article 1483.

rospatent.gov.ru+1

 

6. Pharmaceutical and Biotechnology Trademark Conflicts

One of the most significant areas of Russian biotechnology trademark law concerns confusing similarity between pharmaceutical and biological product names.

The problem arises when two companies use similar names for medicines, vaccines, diagnostic products or other health-related goods.

For example:

Company A markets a monoclonal antibody under Brand X.

Company B introduces a biological medicine under Brand Y.

The names sound similar and the products are sold through overlapping pharmaceutical channels.

Even if the products contain different active ingredients, the similarity of their commercial names may create a legal dispute.

The assessment generally considers:

Visual similarity.

Phonetic similarity.

Semantic similarity.

Overall consumer perception.

Similarity of the relevant goods.

Likelihood of confusion.

Evidence of commercial use and potential bad faith.

The pharmaceutical three-letter approach

Russian pharmaceutical trademark examination has also been associated with a practical three-letter approach to distinguishing medicine names.

The relevant methodological recommendations indicate that differences of at least three characters can be important when comparing pharmaceutical names.

However, this is not an absolute statutory rule. The overall assessment of similarity and confusion remains necessary.

The academic analysis of Russian pharmaceutical trademark practice discusses this approach and the particular problems associated with trademarks resembling international non-proprietary names (INNs).

law-journal.hse.ru+1

 

7. International Non-Proprietary Names and Biotechnology Trademarks

International non-proprietary names are generic names used to identify pharmaceutical substances.

They are particularly important in biotechnology because many biological medicines are based on:

Recombinant proteins.

Monoclonal antibodies.

Hormones.

Enzymes.

Therapeutic biological substances.

A trademark must not improperly prevent other manufacturers from identifying or describing the underlying active substance.

For instance, a company may develop a distinctive brand for a recombinant protein medicine, but it cannot ordinarily claim exclusive ownership of the generic scientific name of that protein.

The legal distinction is:

Generic scientific nameCommercial trademark
Identifies a substanceIdentifies commercial origin
Generally available for legitimate useExclusive rights may arise through registration
Not ordinarily monopolised by one manufacturerMay be protected against confusing commercial use
Supports scientific and medical communicationSupports brand recognition

This distinction protects both commercial innovation and the ability of healthcare professionals to communicate accurately.

8. Ownership and Exclusive Rights

Article 1484 provides the registered trademark owner with an exclusive right to use the trademark for the goods and services covered by registration.

In biotechnology, this right can apply to:

Product packaging.

Medicine labels.

Vaccine containers.

Diagnostic-kit packaging.

Laboratory documentation.

Commercial websites.

Product catalogues.

Advertising materials.

Domain names.

A competitor cannot use an identical or confusingly similar designation for identical or homogeneous goods where that use may cause confusion.

The owner may also prevent unauthorised commercial use of a protected mark.

Article 1485 permits the use of the registered trademark symbol, including ®, to indicate protection.

rospatent.gov.ru

 

Ownership in biotechnology collaborations

Ownership questions become particularly complicated when biotechnology research involves several organisations.

For example:

A university develops a diagnostic technology.

A pharmaceutical company funds its commercialisation.

A biotechnology start-up develops the product brand.

A contract manufacturer produces the final product.

The parties should clearly specify:

Who owns the trademark.

Who controls the brand.

Who may use the mark.

Who is responsible for product quality.

Whether sublicensing is permitted.

What happens when the research collaboration ends.

A trademark licence does not automatically transfer ownership of the underlying patent, scientific research, genetic sequence or manufacturing know-how.

9. Trademark Licensing and Technology Commercialisation

Article 1489 governs trademark licensing.

A biotechnology trademark owner may permit another company to use its mark under a written licence agreement.

Examples include:

A. Pharmaceutical licensing

A biotechnology developer licenses its product brand to a pharmaceutical manufacturer.

B. Contract manufacturing

A company permits a third-party manufacturer to produce products under its registered trademark.

C. Research partnerships

A biotechnology business permits a research institution to use its mark in authorised commercial research activities.

D. International distribution

A Russian trademark owner authorises a foreign distributor to market its products under the protected brand, subject to applicable territorial and contractual requirements.

An important feature of Article 1489 is that the licensee must maintain the quality standards established by the licensor. The licensor may monitor compliance, and both parties may bear liability for claims relating to the licensee's goods.

Article 1490 also requires the relevant trademark licensing and assignment agreements to be in writing and registered as prescribed by law.

rospatent.gov.ru+1

 

10. Trademark Infringement in the Biotechnology Sector

Trademark infringement occurs when a person unlawfully uses a protected designation in circumstances covered by the exclusive rights of the trademark owner.

Common biotechnology-related examples include:

Selling counterfeit biological medicines.

Using another company's vaccine brand.

Copying the logo of a biotechnology laboratory.

Marketing unauthorised genetic-testing services under a competitor's brand.

Using confusingly similar names on diagnostic kits.

Importing or distributing products bearing counterfeit labels.

Using a protected pharmaceutical trademark in misleading online advertising.

Legal remedies

Under Article 1515 of the Civil Code, the trademark owner may seek:

Withdrawal of counterfeit goods from commercial circulation.

Destruction of counterfeit goods or labels, subject to statutory exceptions.

Removal of infringing designations from advertising and commercial materials.

Compensation instead of damages.

Other applicable civil-law remedies.

Article 1515 provides alternative compensation mechanisms, including:

A discretionary amount between 10,000 and 5,000,000 roubles.

Double the value of the goods bearing the unlawful trademark.

Double the assessed value of the right to use the trademark.

The applicable statutory calculation and the court's assessment depend on the circumstances of the infringement.

rospatent.gov.ru+1

 

In biotechnology cases, enforcement may also require coordination with pharmaceutical regulators where the disputed product raises independent questions concerning product authorisation, labelling or patient safety.

11. Important Case Laws and Legal Decisions

Russian biotechnology trademark law is significantly influenced by pharmaceutical trademark disputes. Although not every pharmaceutical case concerns biotechnology specifically, these decisions are highly relevant to biological medicines, vaccines, diagnostic products and other life-science goods.

Case 1: Cardiomagnyl v. Magnikardil (2025)

Important pharmaceutical trademark decision

Authority: Rospatent Chamber for Patent Disputes

Decision: 30 December 2025.

Facts:

A Russian pharmaceutical company challenged the registration of the trademark MAGNIKARDIL, Registration Certificate No. 827772.

The company argued that MAGNIKARDIL was confusingly similar to its earlier, well-known trademark CARDIOMAGNYL.

The marks contained similar elements, including KARD, MAGN and the ending IL. Although the elements appeared in a different order, the competing products were associated with similar therapeutic purposes and the same active ingredient.

Legal issue:

Whether rearranging similar linguistic elements was sufficient to distinguish the later trademark from the earlier protected trademark.

Decision:

The Chamber for Patent Disputes accepted the objection and upheld the invalidation of the MAGNIKARDIL trademark in full.

Legal principles:

Visual differences do not necessarily eliminate phonetic or semantic similarity.

The overall impression of a trademark must be considered.

The characteristics of the relevant pharmaceutical products are important.

Rearranging similar elements does not automatically avoid trademark infringement.

Importance for biotechnology:

The reasoning is relevant to competing brands for monoclonal antibodies, recombinant medicines, therapeutic proteins and biological preparations.

Source: A.Zalesov & Partners – Cardiomagnyl/Magnikardil dispute.

Case 2: VITA / VITA Express Pharmaceutical Trademark Dispute (2019)

Authority: Rospatent Chamber for Patent Disputes.

Decision: 2019.

Facts:

A competing pharmaceutical business used a logo containing the word VITA and a similar colour combination to those used by the established pharmaceutical chain VITA/VITA Express.

The competing business had registered its logo as a trademark.

The established pharmaceutical chain challenged the registration, arguing that the competitor's branding could mislead consumers regarding the commercial source of pharmaceutical products.

Legal issue:

Whether a registered trademark could remain protected when its use and presentation created consumer confusion and involved unfair commercial conduct.

Decision:

The Rospatent Chamber for Patent Disputes invalidated the competing trademark in full.

Legal principles:

Trademark registration does not legitimise unfair commercial conduct.

Consumer confusion is relevant when evaluating trademark protection.

Earlier commercial identity and market circumstances may be important evidence.

Similar logos and colour combinations may contribute to misleading commercial presentation.

Importance for biotechnology:

This decision is relevant to biotechnology companies operating diagnostic laboratories, pharmaceutical distribution networks and biological-product businesses.

A competitor should not imitate the commercial identity of an established biotechnology company to create an impression of common ownership or commercial affiliation.

Source: EPAM Law – VITA pharmaceutical trademark dispute.

Case 3: Pharmaceutical Trademark Registration Dispute (Russian IP Court, 27 March 2026)

Recent IP Court decision

Authority: Russian Intellectual Property Court.

Decision: 27 March 2026.

Facts:

A pharmaceutical company applied to register a trademark for medicinal products in Class 5.

Rospatent refused registration because it considered the proposed mark confusingly similar to earlier registered trademarks.

The applicant subsequently resolved disputes with the owners of the conflicting marks through consent letters and a trademark assignment agreement.

However, the transfer of exclusive rights to one of the relevant trademarks had not been registered when Rospatent considered the matter.

Legal issue:

Whether Rospatent could continue refusing registration when the legal circumstances underlying the earlier refusal had changed and the applicant had addressed the conflicting rights.

Decision:

On 27 March 2026, the Intellectual Property Court invalidated Rospatent's refusal and ordered registration of the applicant's designation for all the claimed pharmaceutical goods in Class 5.

Legal principles:

Earlier trademark rights must be assessed in light of the legally relevant circumstances.

Trademark assignments and consent arrangements can affect registration obstacles.

Registration of transfers is important when establishing the legal status of exclusive rights.

Administrative trademark decisions may be challenged before the Intellectual Property Court.

Importance for biotechnology:

This decision is relevant to biotechnology companies seeking to register new brands for biological medicines, vaccines and diagnostic preparations when earlier pharmaceutical trademarks create registration obstacles.

Source: A.Zalesov & Partners – Russian IP Court pharmaceutical trademark decision.

Case-law qualification: The first two examples concern decisions of Rospatent's specialist dispute body, not ordinary court judgments. The third concerns a judicial decision. They should not be treated as three Supreme Court precedents.

12. Trademark Non-Use and Biotechnology Commercialisation

Article 1486 of the Russian Civil Code establishes an important requirement concerning commercial use.

A trademark may be subject to early termination if it has not been used continuously for three years in relation to the registered goods.

This creates particular problems for biotechnology businesses.

For example, a company may register a trademark for a biological medicine but delay commercialisation because:

Clinical trials are incomplete.

Regulatory approval has not been obtained.

Manufacturing facilities are not ready.

Production technology requires further development.

Distribution arrangements have failed.

Financing is unavailable.

An interested party may initiate the statutory procedure seeking termination of the unused trademark.

The procedure generally requires:

Sending a formal proposal to the trademark owner.

Allowing the statutory two-month response period.

Filing the appropriate court claim within the prescribed subsequent 30-day period if the matter remains unresolved.

Establishing non-use during the relevant three-year period.

The trademark owner bears the burden of proving genuine use. Evidence of circumstances beyond its control may also be relevant.

This is especially important for biotechnology businesses because development and regulatory approval may take several years.

rospatent.gov.ru

 

13. Biotechnology Trademark Protection and Public Health

Trademark law in biotechnology has an important relationship with public health.

A misleading trademark can cause problems in identifying the source of medicines, vaccines and diagnostic products.

Consider the following hypothetical situation:

A company markets a biological medicine using a name that closely resembles the brand of an established manufacturer. Healthcare providers mistakenly believe that the products come from the same manufacturer.

This could create risks involving:

Product identification.

Pharmaceutical distribution.

Medical procurement.

Product traceability.

Patient communication.

Pharmacovigilance.

Trademark law addresses commercial identification and confusion. However, it does not replace the separate safety, quality and marketing-authorisation requirements governing medicines.

Under Russian medicines legislation, the marketing and circulation of medicinal products are subject to their own regulatory framework.

Therefore, a company must satisfy both intellectual-property requirements and applicable pharmaceutical regulatory requirements.

14. Biotechnology Trademark Disputes and Competition Law

The relationship between trademark law and competition law is another important issue.

Federal Law No. 135-FZ on Protection of Competition addresses unfair competition, including conduct involving the unlawful use of intellectual-property rights and the creation of confusion between competing businesses.

Biotechnology-related examples include:

A. Trademark imitation

A competitor copies the name or logo of an established biotechnology company.

B. Misleading commercial presentation

A manufacturer presents its diagnostic products in a manner suggesting an association with a recognised biotechnology laboratory.

C. Unfair registration

A business attempts to register a designation that it knows is associated with another company's established commercial identity.

D. Misleading product advertising

A company uses a competitor's trademark to promote its own biological medicines or diagnostic services.

These circumstances may create both trademark and competition-law issues.

15. International Trademark Protection for Russian Biotechnology Companies

Russian biotechnology businesses may seek trademark protection outside Russia.

Two important international routes are:

The Madrid System administered by the World Intellectual Property Organization (WIPO).

Direct national trademark applications in individual countries.

The Madrid System enables applicants to seek trademark protection in designated jurisdictions through an international registration based on the applicable national or regional basic application or registration.

However, international registration does not guarantee acceptance in every designated country. Each relevant jurisdiction may examine the mark under its own legislation.

For biotechnology companies, international protection is important when exporting:

Vaccines.

Biological medicines.

Diagnostic kits.

Genetic testing products.

Laboratory equipment.

Biotechnology research services.

International applications should also take account of pharmaceutical naming requirements and the availability of the proposed brand in each target market.

16. Major Legal Challenges in Russian Biotechnology Trademark Law

Legal challengeMain concernRelevant legal provision
Generic scientific terminologyMonopoly over scientific namesArticle 1483
Similar pharmaceutical brandsConsumer confusionArticles 1483 and 1484
Vaccine brand imitationUnauthorised commercial identityArticles 1484 and 1515
Genetic-testing brand disputesConfusion between service providersArticles 1477 and 1484
Biotechnology trademark licensingQuality control and contractual complianceArticle 1489
Trademark non-useCancellation after three yearsArticle 1486
Trademark ownership transferConsumer deception and registrationArticles 1488–1490
Counterfeit biological productsUnlawful trademark useArticle 1515
International trademark disputesTerritorial protection and recognitionRelevant international treaties

17. Recommendations for Biotechnology Companies Operating in Russia

Biotechnology companies should adopt a comprehensive trademark-protection strategy.

First, conduct trademark clearance before launching a product.

Search existing registrations for pharmaceutical, biological and diagnostic goods.

Second, select distinctive commercial names.

Avoid names consisting exclusively of generic scientific expressions, biological substances or standard medical terminology.

Third, protect the relevant Nice Classification classes.

A biotechnology company may need protection across Classes 1, 5, 9, 10, 42 and 44, depending on its commercial activities.

Fourth, coordinate trademark and regulatory compliance.

Ensure that the commercial brand does not create confusion regarding a medicine's approved identity, characteristics or regulatory status.

Fifth, establish contractual ownership.

Research agreements, technology-transfer agreements, manufacturing contracts and licensing arrangements should clearly allocate trademark ownership and usage rights.

Sixth, monitor competing trademarks.

Companies should monitor new registrations, similar pharmaceutical names, counterfeit products and unauthorised online commercial use.

Seventh, maintain evidence of use.

Preserve invoices, distribution agreements, product packaging, advertising records and other evidence demonstrating genuine commercial use.

18. Conclusion

Biotechnology Trademark Law in Russia is an important component of the country's intellectual-property and pharmaceutical regulatory framework.

Part IV of the Russian Civil Code provides the principal legal foundation for trademark registration, exclusive rights, licensing, assignments, non-use termination and infringement remedies.

The most important issues arise from the relationship between scientific terminology and commercial identification. Biotechnology businesses must be able to protect distinctive product brands without monopolising generic scientific names or preventing legitimate competition.

The pharmaceutical disputes involving CARDIOMAGNYL and MAGNIKARDIL, VITA/VITA Express, and the 2026 Russian Intellectual Property Court registration decision demonstrate the practical importance of distinctiveness, consumer confusion, earlier trademark rights and proper registration of trademark transfers.

Ultimately, effective trademark governance in Russian biotechnology requires coordination between intellectual-property law, pharmaceutical regulation, competition law, contractual arrangements and public-health protections.

19. Important Legal Sources and Further Reading

Russian Civil Code – Official English translation, Part IV.

Rospatent – Russian intellectual-property legislation.

Rospatent – Guidelines for Examination of Trademark Applications.

Some Peculiarities of Registration of Pharmaceutical Trademarks.

WIPO Lex – Russian Federation intellectual-property legislation and judgments.

Rospatent – Trademark protection and registration guidance.

Academic note: This is a general legal research explanation, not an individual legal opinion. For litigation or commercial registration, the latest Russian legislation, official Rospatent records and the complete texts of relevant judicial decisions should be checked.

LawGratis provides pro bono legal aid and resources to empower communities. Join us in making justice reachable for everyone! Follow our community on Instagram, YouTube, Facebook, and LinkedIn.

LEAVE A COMMENT